keyword
Keywords Hyperthermic intraperitoneal c...

Hyperthermic intraperitoneal chemotherapy

https://read.qxmd.com/read/38498087/aso-author-reflections-addressing-hospital-based-disparities-in-access-to-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-crs-hipec-and-survival-in-patients-with-isolated-colorectal-peritoneal-metastases
#1
JOURNAL ARTICLE
Roos G F M van der Ven, Teun B M van den Heuvel, Koen P B Rovers, Simon W Nienhuijs, Felice N van Erning, Ignace H J T de Hingh
No abstract text is available yet for this article.
March 18, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38491312/retrospective-evaluation-of-the-prognostic-value-of-histological-growth-pattern-in-patients-with-colorectal-peritoneal-metastases-undergoing-curative-intent-cytoreductive-surgery
#2
JOURNAL ARTICLE
Leonel Kamdem, Antoine El Asmar, Pieter Demetter, Ismael Coulibaly Zana, Charif Khaled, Francesco Sclafani, Vincent Donckier, Peter Vermeulen, Gabriel Liberale
BACKGROUND: Two distinct histological growth patterns (HGPs) were described in patients with peritoneal metastasis of colorectal cancer origin (PMCRC) with limited Peritoneal Cancer Index (PCI) ≤ 6 who did not receive neoadjuvant chemotherapy (NAC) and were treated with cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC): pushing HGP (P-HGP) and infiltrating HGP (I-HGP). Patients with dominant P-HGP (> 50%) had significantly better disease-free survival (DFS) and overall survival (OS)...
March 15, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38486378/rare-case-of-recurrent-adamantinoma-of-the-tibia-limited-efficacy-of-pazopanib-as-a-standalone-treatment
#3
JOURNAL ARTICLE
Mahmoud Elshenawy, Sarah Khaled Aldahoul, Abduljalil Mohamed El-Sibai, Alaa Hamad, Tarek Ziad Arabi, Saleha Abdul Rab, Ahmed Badran, Tariq Alzaid, Belal Nedal Sabbah, Jean Paul Atallah
BACKGROUND Adamantinoma is a rare low-grade malignant bone tumor, usually found in the tibial diaphysis and metaphysis, with histological similarities to mandibular ameloblastoma. The most effective treatment of recurrent adamantinoma is not yet clear. This report is of a 22-year-old woman with recurrent tibial adamantinoma treated with the tyrosine kinase inhibitor pazopanib. CASE REPORT We report the case of a 22-year-old woman who was referred to our center for a suspicious bone lesion in the right tibia...
March 15, 2024: American Journal of Case Reports
https://read.qxmd.com/read/38475933/surgical-and-survival-outcomes-of-early-onset-colorectal-cancer-patients-a-single-centre-descriptive-australian-study
#4
JOURNAL ARTICLE
Celine Garrett, Daniel Steffens, Michael Solomon, Cherry Koh
BACKGROUND: Early-onset colorectal cancer (EOCRC) incidence is increasing in Australia. However, no Australian studies have reported on EOCRC patients' surgical management and survival patterns. METHODS: A retrospective study of 111 EOCRC patients treated at the Royal Prince Alfred Hospital (RPAH), Sydney, Australia between January 2013 and December 2021 was performed. RPAH is a quaternary referral centre for pelvic exenteration (PE) and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)...
March 12, 2024: ANZ Journal of Surgery
https://read.qxmd.com/read/38472928/successful-implementation-of-hitoc-and-hipec-in-the-management-of-advanced-ovarian-carcinoma-with-pleural-and-peritoneal-carcinomatosis
#5
JOURNAL ARTICLE
Bogdan Moldovan, Codin Theodor Saon, Iris-Iuliana Adam, Radu-Mihai Pisica, Vlad Teodor Silaghi, Vlad Untaru, Doly Stoica, Madalina Crisan, Andreea Popianas, Florentina Pescaru, Adriana Zolog, Liliana Vecerzan
This case report details the application and outcomes of a novel therapeutic approach involving hyperthermic intraperitoneal chemotherapy (HIPEC) and hyperthermic intrathoracic chemotherapy (HITOC) in a single patient diagnosed with advanced ovarian neoplasm. The treatment protocol included pleural cytoreductive surgery (CRS) and HITOC followed by a second surgical intervention consisting of peritoneal CRS and HIPEC. HIPEC targeted the intraperitoneal space with heated chemotherapy, while HITOC extended the thermal perfusion to the thoracic cavity...
February 20, 2024: Diagnostics
https://read.qxmd.com/read/38466484/improved-postoperative-pain-management-outcomes-after-implementation-of-enhanced-recovery-after-surgery-eras-protocol-for-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-crs-hipec
#6
JOURNAL ARTICLE
Tiffany M Yue, Beatrice J Sun, Nova Xu, Rika Ohkuma, Cedar Fowler, Byrne Lee
BACKGROUND: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for patients with peritoneal carcinomatosis is promising but has potential for significant morbidity and prolonged hospitalization. Enhanced Recovery After Surgery (ERAS) is a standardized protocol designed to optimize perioperative care. This study describes trends in epidural and opioid use after implementing ERAS for CRS-HIPEC at a tertiary academic center. METHODS: A retrospective analysis of patients undergoing CRS-HIPEC from January 2020 to September 2023 was conducted...
March 11, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38460291/cytoreduction-surgery-crs-with-hyperthermic-intraperitoneal-chemotherapy-hipec-as-treatment-choice-of-metastatic-urachal-carcinoma
#7
Giorgio Micheletti, Vincenzo Ricchiuti, Ludovico Carbone, Noemi La Francesca, Roberto Petrioli, Daniele Marrelli
INTRODUCTION: Urachal carcinoma accounts for approximately 0.01 % of all adult malignancies and 1 % of bladder cancers. Its prognosis remains poor, with a 5-year overall survival rate of less than 50 %. PRESENTATION OF CASE: A 51-years-old black female, affected by peritoneal malignancies from urachal carcinoma, underwent multiple surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with different chemotherapy regimen, alternating with intravenous chemotherapy...
March 4, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38453961/comprehensive-multi-omics-analysis-reveals-wee1-as-a-synergistic-lethal-target-with-hyperthermia-through-cdk1-super-activation
#8
JOURNAL ARTICLE
Xiaohang Yang, Xingyuan Hu, Jingjing Yin, Wenting Li, Yu Fu, Bin Yang, Junpeng Fan, Funian Lu, Tianyu Qin, Xiaoyan Kang, Xucui Zhuang, Fuxia Li, Rourou Xiao, Tingyan Shi, Kun Song, Jing Li, Gang Chen, Chaoyang Sun
Hyperthermic intraperitoneal chemotherapy's role in ovarian cancer remains controversial, hindered by limited understanding of hyperthermia-induced tumor cellular changes. This limits developing potent combinatory strategies anchored in hyperthermic intraperitoneal therapy (HIPET). Here, we perform a comprehensive multi-omics study on ovarian cancer cells under hyperthermia, unveiling a distinct molecular panorama, primarily characterized by rapid protein phosphorylation changes. Based on the phospho-signature, we pinpoint CDK1 kinase is hyperactivated during hyperthermia, influencing the global signaling landscape...
March 7, 2024: Nature Communications
https://read.qxmd.com/read/38453767/towards-equal-access-to-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-and-survival-in-patients-with-isolated-colorectal-peritoneal-metastases-a-nationwide-population-based-study
#9
JOURNAL ARTICLE
Roos G F M van der Ven, Teun B M van den Heuvel, Koen P B Rovers, Simon W Nienhuijs, Djamila Boerma, Wilhelmina M U van Grevenstein, Patrick H J Hemmer, Niels F M Kok, Eva V E Madsen, Philip de Reuver, Jurriaan B Tuynman, Felice N van Erning, Ignace H J T de Hingh
BACKGROUND: Before 2016, patients with isolated synchronous colorectal peritoneal metastases (PMCRC) diagnosed in expert centers had a higher odds of undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and better overall survival (OS) than those diagnosed in referring centers. Nationwide efforts were initiated to increase awareness and improve referral networks. METHODS: This nationwide study aimed to evaluate whether the between-center differences in odds of undergoing CRS-HIPEC and OS have reduced since these national efforts were initiated...
March 7, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38450829/complexity-of-surgery-and-treatment-burden-in-patients-with-peritoneal-malignancy-is-not-determined-by-addition-of-hyperthermic-intraperitoneal-chemotherapy
#10
JOURNAL ARTICLE
Daniel Steffens, Nabila Ansari, Cherry Koh, Nima Ahmadi, Michael J Solomon, Sophie Hogan, Sascha Karunaratne, Teresa Anderson, Kiel Harvey, Kate McBride, Brendan Moran
BACKGROUND: This study describes surgical and quality of life outcomes in patients with peritoneal malignancy treated by cytoreductive surgery (CRS) alone compared with a subgroup treated with CRS and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: Peritoneal malignancy patients undergoing surgery between 2017 and 2023 were included. The cohort was divided into patients treated by CRS and HIPEC and those treated by CRS without HIPEC (including CRS only or maximal tumour debulking (MTB))...
March 7, 2024: ANZ Journal of Surgery
https://read.qxmd.com/read/38439639/the-importance-of-integrating-diagnostic-modalities-in-patient-selection-for-crs-hipec-in-colorectal-peritoneal-metastases
#11
JOURNAL ARTICLE
Nadine L de Boer, Checca Bakkers, Alexandra Rm Brandt-Kerkhof, Marianne de Vries, Joost Nederend, Cornelis Verhoef, Ignace Hjt de Hingh, Jacobus Wa Burger
BACKGROUND: Despite thorough preoperative work-up for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), so called open-close (OC) procedures as a result of irresectable disease remain common. Currently, diagnostic laparoscopy (DLS) is considered the gold standard, and consequently overrules the results of computed tomography (CT) scans; however, certain regions of the abdomen are difficult to assess and postoperative adhesion formation may further compromise staging during DLS...
March 4, 2024: Acta Radiologica
https://read.qxmd.com/read/38437211/efficacy-of-hyperthermic-intraperitoneal-chemotherapy-in-colorectal-cancer-a-phase-i-and-iii-open-label-randomized-controlled-registry-based-clinical-trial-protocol
#12
JOURNAL ARTICLE
Lana Ghanipour, Gabriella Jansson Palmer, Per J Nilsson, Caroline Nordenvall, Jan-Erik Frödin, Elinor Bexe Lindskog, Dan Asplund, Torbjörn Swartling, Wilhelm Graf, Helgi Birgisson, Ingvar Syk, Victor Verwaal, Jenny Brändstedt, Peter H Cashin
Standard treatment for patient with peritoneal metastases from colorectal cancer is cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). In recent years, the efficacy of oxaliplatin-based HIPEC has been challenged. An intensified HIPEC (oxaliplatin+irinotecan) in combination with early postoperative intraperitoneal chemotherapy (EPIC) has shown increased recurrence-free survival in retrospective studies. The aim of this trial is to develop a new HIPEC/EPIC regimen and evaluate its effect on morbidity, oncological outcome, and quality-of-life (QoL)...
2024: PloS One
https://read.qxmd.com/read/38433868/phase-1-trial-of-same-day-cytology-to-guide-the-use-of-hipec
#13
JOURNAL ARTICLE
Paul H Sugarbaker, Tom Deng
BACKGROUND: Peritoneal metastases from gastrointestinal or gynecologic malignancy are a prominent part of the natural history of these diseases. Peritoneal metastases, if not effectively treated, will result in a decreased survival and cause an impaired quality of life. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment specifically designed to combat peritoneal metastases. A group of patients who, from a theoretical perspective, may benefit from HIPEC are those patients with a positive peritoneal cytology...
March 2024: International journal of surgery protocols
https://read.qxmd.com/read/38430428/initial-experience-using-laparoscopic-hipec-for-gastric-cancer-with-peritoneal-metastasis-safety-and-outcomes
#14
JOURNAL ARTICLE
Meagan D Read, Justin Drake, Ghazal Hashemipour, Benjamin D Powers, Rutika Mehta, Andrew Sinnamon, Jose M Pimiento, Sean P Dineen
BACKGROUND: Peritoneal metastases (PM) develop in approximately 20% of patients with gastric cancer (GC). For selected patients, treatment of PM with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has shown promising results. This report aims to describe the safety and perioperative outcomes of laparoscopic HIPEC for GC/PM. METHODS: This retrospective cohort study evaluated patients who had GC and PM treated with laparoscopic HIPEC (2018-2022)...
March 2, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38429574/hyperthermic-pressurized-intraperitoneal-aerosol-drug-delivery-system-in-a-large-animal-model-a-feasibility-and-safety-study
#15
JOURNAL ARTICLE
Sa-Hong Min, Mira Yoo, Duyeong Hwang, Eunju Lee, So Hyun Kang, Sangjun Lee, Yongjoon Won, Young Suk Park, Sang-Hoon Ahn, Hyung-Ho Kim
BACKGROUND: We developed a novel drug delivery system called hyperthermic pressurized intraperitoneal aerosol chemotherapy (HPIPAC) that hybridized Hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC). The present study aims to assess the feasibility and safety of HPIPAC system in a large animal survival model. METHODS: Eleven pigs (eight non-survival models and three survival models) were used in the experiment...
March 1, 2024: Surgical Endoscopy
https://read.qxmd.com/read/38411761/expanding-the-use-of-hipec-in-ovarian-cancer-at-time-of-interval-debulking-surgery-to-figo-stage-iv-and-after-6-cycles-of-neoadjuvant-chemotherapy-a-prospective-analysis-on-perioperative-and-oncologic-outcomes
#16
JOURNAL ARTICLE
Valentina Ghirardi, Rita Trozzi, Francesca Romana Scanu, Diana Giannarelli, Francesco Santullo, Barbara Costantini, Angelica Naldini, Camilla Panico, Luciano Frassanito, Giovanni Scambia, Anna Fagotti
BACKGROUND: Randomized data on patients with FIGO stage III ovarian cancer receiving ≤ 3 cycles of neoadjuvant chemotherapy (NACT) showed that hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS) improved patient's survival. We assessed the perioperative outcomes and PFS of FIGO stage IV and/or patients receiving up to 6 cycles of NACT undergoing IDS+HIPEC. METHODS: Prospectively collected cases from January 1, 2019 to July 31, 2022 were included...
February 27, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38406052/lower-gastrointestinal-bleeding-secondary-to-appendiceal-mucinous-neoplasm-a-report-of-two-cases-and-a-review-of-the-literature
#17
Jesús Omar Soto Llanes, Samanta Kin Dosal Limón, Ana Jimena Iberri Jaime, Mario Zambrano Lara, Billy Jiménez Bobadilla
Appendicular mucinous neoplasms, constituting less than 1% of gastrointestinal tract neoplasms, are heterogeneous entities. They may be asymptomatic, discovered incidentally, or present as large tumors due to mucin accumulation. The lack of standardized treatment complicates management. Imaging studies, particularly CT scans, are crucial for diagnosis and follow-up. This case report presents two clinical cases of women in their sixth and seventh decades of life with a history of lower gastrointestinal bleeding, mild anemia in laboratory studies, and incomplete colonoscopies...
January 2024: Curēus
https://read.qxmd.com/read/38392042/paclitaxel-as-hipec-drug-after-surgical-cytoreduction-for-ovarian-peritoneal-metastases-a-randomized-phase-iii-clinical-trial-hipecova
#18
JOURNAL ARTICLE
Pedro Villarejo Campos, Susana Sánchez García, Mariano Amo-Salas, Esther García Santos, Carlos López de la Manzanara, Ana Alberca, David Padilla-Valverde, Francisco Javier Redondo Calvo, Jesús Martín
Multidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conducted between August 2012 and December 2019. Seventy-six patients were randomized to either the HIPEC or no HIPEC group. Although median values for the primary endpoints (recurrence-free survival (RFS) and overall survival (OS)) revealed superior outcomes for the HIPEC (RFS: 23 months, OS: 48 months) over the control group (RFS: 19 months, OS: 46 months), these differences were not statistically significant ( p = 0...
January 24, 2024: Current Oncology
https://read.qxmd.com/read/38390578/laparoscopic-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-gastric-cancer-with-intraoperative-detection-of-limited-peritoneal-metastasis-a-phase-ii-study-of-class-05-trial
#19
JOURNAL ARTICLE
Tian Lin, Xinhua Chen, Zhijun Xu, Yanfeng Hu, Hao Liu, Jiang Yu, Guoxin Li
BACKGROUND: Systemic chemotherapy for gastric cancer with peritoneal metastasis has limited clinical benefit; for those with intraoperative detection of occult peritoneal metastasis, cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is an alternative treatment. However, the feasibility and effects of this modality and criteria for selecting suitable groups remain unclear. This study aimed to explore the safety and efficacy of laparoscopic cytoreductive surgery (L-CRS) followed by HIPEC in gastric cancer with limited peritoneal metastasis, and this study also aimed to determine the optimized cut-off of the peritoneal cancer index...
2024: Gastroenterology Report
https://read.qxmd.com/read/38390264/global-trends-in-research-of-pseudomyxoma-peritonei-a-bibliometric-and-visualization-analysis
#20
Shuo Liu, Xue Liu, Ruiqing Ma, Shuang Yu, Liangyuan Lu, Yanjun Lin, Zhanmin Yang
OBJECTIVE: Pseudomyxoma peritonei (PMP) was a complex disease that had attracted increasing attention. However, there had been no bibliometric analysis of this disease so far. This study aimed to explore the current situation and frontier trend of PMP through bibliometric and visualization analysis, and to indicate new directions for future research. METHODS: The original research articles and reviews related to the PMP research were downloaded from Web of Science Core Collection on September 11, 2023...
2024: Frontiers in Oncology
keyword
keyword
23492
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.